These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 32871009)

  • 1. The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction.
    Withaar C; Meems LMG; Markousis-Mavrogenis G; Boogerd CJ; Silljé HHW; Schouten EM; Dokter MM; Voors AA; Westenbrink BD; Lam CSP; de Boer RA
    Cardiovasc Res; 2021 Jul; 117(9):2108-2124. PubMed ID: 32871009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway.
    Ni XY; Feng XJ; Wang ZH; Zhang Y; Little PJ; Cao Y; Xu SW; Tang LQ; Weng JP
    Acta Pharmacol Sin; 2024 Aug; 45(8):1604-1617. PubMed ID: 38589689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction.
    Zhang N; Feng B; Ma X; Sun K; Xu G; Zhou Y
    Cardiovasc Diabetol; 2019 Aug; 18(1):107. PubMed ID: 31429767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling.
    Zhang Y; Lin X; Chu Y; Chen X; Du H; Zhang H; Xu C; Xie H; Ruan Q; Lin J; Liu J; Zeng J; Ma K; Chai D
    Cardiovasc Diabetol; 2021 Jun; 20(1):121. PubMed ID: 34116674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload.
    Shi L; Zhu D; Wang S; Jiang A; Li F
    Am J Hypertens; 2019 Apr; 32(5):452-459. PubMed ID: 30689697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
    Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
    Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
    Lee HC; Shiou YL; Jhuo SJ; Chang CY; Liu PL; Jhuang WJ; Dai ZK; Chen WY; Chen YF; Lee AS
    Cardiovasc Diabetol; 2019 Apr; 18(1):45. PubMed ID: 30935417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exogenous supplement of glucagon like peptide-1 protects the heart against aortic banding induced myocardial fibrosis and dysfunction through inhibiting mTOR/p70S6K signaling and promoting autophagy.
    Zheng RH; Zhang WW; Ji YN; Bai XJ; Yan CP; Wang J; Bai F; Zhao ZQ
    Eur J Pharmacol; 2020 Sep; 883():173318. PubMed ID: 32621911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis.
    Gaspari T; Brdar M; Lee HW; Spizzo I; Hu Y; Widdop RE; Simpson RW; Dear AE
    Diab Vasc Dis Res; 2016 Jan; 13(1):56-68. PubMed ID: 26408644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction.
    Connelly KA; Zhang Y; Desjardins JF; Thai K; Gilbert RE
    Cardiovasc Diabetol; 2018 Jul; 17(1):99. PubMed ID: 29981571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of myocardial injury and collagen deposition following ischaemia-reperfusion by linagliptin and liraglutide, and both together.
    Wang X; Ding Z; Yang F; Dai Y; Chen P; Theus S; Singh S; Budhiraja M; Mehta JL
    Clin Sci (Lond); 2016 Aug; 130(15):1353-62. PubMed ID: 27129181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a growth hormone-releasing hormone agonist in a murine model of cardiometabolic heart failure with preserved ejection fraction.
    Kanashiro-Takeuchi RM; Takeuchi LM; Dulce RA; Kazmierczak K; Balkan W; Cai R; Sha W; Schally AV; Hare JM
    Am J Physiol Heart Circ Physiol; 2023 Jun; 324(6):H739-H750. PubMed ID: 36897749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay.
    Chen H; Tran D; Yang HC; Nylander S; Birnbaum Y; Ye Y
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):443-461. PubMed ID: 32335797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining three independent pathological stressors induces a heart failure with preserved ejection fraction phenotype.
    Li Y; Kubo H; Yu D; Yang Y; Johnson JP; Eaton DM; Berretta RM; Foster M; McKinsey TA; Yu J; Elrod JW; Chen X; Houser SR
    Am J Physiol Heart Circ Physiol; 2023 Apr; 324(4):H443-H460. PubMed ID: 36763506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients: a meta-analysis.
    Albulushi A; Tanoh DB; Almustafa A; Al Matrooshi N; Zolty R; Lowes B
    Cardiovasc Diabetol; 2024 Aug; 23(1):324. PubMed ID: 39217337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a mouse model of obesity-related fibrotic cardiomyopathy that recapitulates features of human heart failure with preserved ejection fraction.
    Alex L; Russo I; Holoborodko V; Frangogiannis NG
    Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H934-H949. PubMed ID: 30004258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telmisartan ameliorates cardiac fibrosis and diastolic function in cardiorenal heart failure with preserved ejection fraction.
    Chang D; Xu TT; Zhang SJ; Cai Y; Min SD; Zhao Z; Lu CQ; Wang YC; Ju S
    Exp Biol Med (Maywood); 2021 Dec; 246(23):2511-2521. PubMed ID: 34342551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench.
    Shih JY; Lin YW; Fisch S; Cheng JT; Kang NW; Hong CS; Chen ZC; Chang WT
    Diabetes; 2021 Jan; 70(1):262-267. PubMed ID: 33115828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin protects against heart failure with preserved ejection fraction partly by inhibiting the senescence-associated STAT1-STING axis.
    Shi Y; Zhao L; Wang J; Liu X; Bai Y; Cong H; Li X
    Cardiovasc Diabetol; 2024 Jul; 23(1):269. PubMed ID: 39044275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myocardial reverse remodeling: how far can we rewind?
    Rodrigues PG; Leite-Moreira AF; Falcão-Pires I
    Am J Physiol Heart Circ Physiol; 2016 Jun; 310(11):H1402-22. PubMed ID: 26993225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.